Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Investigational

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Cyclin-dependent kinase 4

1

Cyclin-dependent kinase 9

1

Cyclin-dependent kinase-like 5

1

Serine/threonine-protein kinase ICK

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Phase II

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

3

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Adult acute megakaryoblastic leukemia

1

Breast cancer

1

Chronic lymphocytic leukemia

1

Head and neck cancer

1

Thromboembolism

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Nygaard, A.P.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Protein

2

Chemical

1

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

FDA ORPHAN DRUG

3

FDA UNII

3

INN

2

NCI_THESAURUS

2

All Match

Any Match

Exclude Selected

Exclude Selected

Protein Type

BISPECIFIC ANTIBODY

1

MONOCLONAL ANTIBODY

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for "ORPHAN DRUG|Designated|Treatment of Ewing sarcoma." in comments (approximate match)

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

Xaluritamig

ODG03B9M4U

Subunit 1 (723) Similarity Search Subunit 2 (450) Similarity Search Subunit 3 (213) Similarity Search Subunit 4 (213) Similarity Search

Export Data
Sequence Search

Subunit 1 (723) Similarity Search Subunit 2 (450) Similarity Search Subunit 3 (213) Similarity Search Subunit 4 (213) Similarity Search

Status:

Investigational

Class:

PROTEIN

GANITUMAB

CK1441RCZ8

Subunit 1 (449) Similarity Search Subunit 2 (449) Similarity Search Subunit 3 (219) Similarity Search Subunit 4 (219) Similarity Search

Export Data
Sequence Search

Subunit 1 (449) Similarity Search Subunit 2 (449) Similarity Search Subunit 3 (219) Similarity Search Subunit 4 (219) Similarity Search

Status:

Investigational

Class:

PROTEIN

TP-1287

7MPP85IIJ3

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Cyclin-dependent kinase 9

Cyclin-dependent kinase-like 5

Serine/threonine-protein kinase ICK

Cyclin-dependent kinase 4

Conditions:

Thromboembolism

Head and neck cancer

Adult acute megakaryoblastic leukemia

Chronic lymphocytic leukemia

Alvocidib (also known as Flavopiridol or HMR-1275) is a flavonoid alkaloid CDK9 kinase inhibitor under clinical development for the treatment of acute myeloid leukemia, by Tolero Pharmaceuticals, Inc. As a broad spectrum CDK inhibitor, Alvocidib can ...

inhibit cell cycle progression in either G1 or G2 and induces G1 arrest in either MCF-7 or MDA-MB-468 cells by inhibition of the CDK4 or CDK2 kinase activity. Alvocidib exhibits potent cytotoxicity against a wide variety of tumor cell lines (LNCAP, HCT116, A2780, K562, PC3, and Mia PaCa-2) with IC50 values ranging from 16 nM for LNCAP to 130 nM for K562. Administration of Alvocidib at 7.5 mg/kg for 7 days displays slight antitumor activity against P388 murine leukemia, and active against the human A2780 ovarian carcinoma implanted sc in nude mice). Alvocidib treatment at 1-2.5 mg/kg for 10 days significantly suppresses collagen-induced arthritis in mice in a dose-dependent manner, by inhibiting synovial hyperplasia and joint destruction, whereas serum concentrations of anti-collagen type II (CII) Abs and proliferative responses to CII are maintained. Tolero Pharmaceuticals Inc. announced that the FDA has granted orphan drug designation for Alvocidib, its cyclin-dependent kinase small molecule inhibitor, for the treatment of patients with acute myeloid leukemia.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1